Presentation and Status in Health Basket
Presentation | Basket | Yarpa | Pharmasoft |
---|---|---|---|
Tablets 30 X 1 mg |
12446 | 9648 |
Related information
Dosage
Posology: The recommended dose of rasagiline is 1 mg (one tablet of AZILECT) once daily, to be taken with or without levodopa.
Elderly: No change in dose is required for elderly patients.
Hepatic impairment: Rasagiline is contraindicated in patients with severe hepatic impairment. Rasagiline use in patients with moderate hepatic impairment should be avoided. Caution should be used when initiating
treatment with rasagiline in patients with mild hepatic impairment. In case patients progress from mild to moderate hepatic impairment rasagiline should be stopped.
Renal impairment: No special precautions are required in patients with renal impairment.
Paediatric population: The safety and efficacy of AZILECT in children and adolescents have not been established. There is no relevant use of AZILECT in the paediatric population in the indication Parkinson’s disease.
Method of administration: For oral use. AZILECT may be taken with or without food.
Indications
For the treatment of idiopathic Parkinson”s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Contra-Indications
Hypersensitivity to the active substance or to any of the excipients. Concomitant treatment with other MAO inhibitors or pethidine. At least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with MAOI inhibitors or pethidine. Patients with severe hepatic insufficiency.
Special Precautions
Please contact manufacturer for full information.
Side Effects
Please contact manufacturer for full information.
Drug interactions
Please contact manufacturer for full information.